Zoetis Inc. (NYSE:ZTS) Shares Acquired by Proficio Capital Partners LLC

Proficio Capital Partners LLC increased its stake in Zoetis Inc. (NYSE:ZTS) by 26,137.7% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 497,467 shares of the company’s stock after buying an additional 495,571 shares during the quarter. Proficio Capital Partners LLC owned about 0.11% of Zoetis worth $81,052,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. Hancock Whitney Corp increased its position in shares of Zoetis by 0.3% during the 3rd quarter. Hancock Whitney Corp now owns 18,569 shares of the company’s stock valued at $3,628,000 after purchasing an additional 61 shares during the period. Strategy Asset Managers LLC increased its position in shares of Zoetis by 3.5% during the 3rd quarter. Strategy Asset Managers LLC now owns 1,822 shares of the company’s stock valued at $356,000 after purchasing an additional 62 shares during the period. VeraBank N.A. grew its holdings in shares of Zoetis by 4.1% in the 4th quarter. VeraBank N.A. now owns 1,562 shares of the company’s stock worth $254,000 after acquiring an additional 62 shares during the last quarter. Procyon Advisors LLC grew its holdings in shares of Zoetis by 1.4% in the 4th quarter. Procyon Advisors LLC now owns 4,712 shares of the company’s stock worth $768,000 after acquiring an additional 63 shares during the last quarter. Finally, Deseret Mutual Benefit Administrators grew its holdings in shares of Zoetis by 6.6% in the 4th quarter. Deseret Mutual Benefit Administrators now owns 1,045 shares of the company’s stock worth $170,000 after acquiring an additional 65 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on ZTS shares. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. Barclays lifted their target price on Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. Leerink Partners started coverage on Zoetis in a report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 target price on the stock. Piper Sandler lifted their target price on Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a report on Thursday. Finally, StockNews.com cut Zoetis from a “buy” rating to a “hold” rating in a report on Tuesday. Two equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $215.90.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the business’s stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the transaction, the executive vice president now owns 16,107 shares in the company, valued at $2,757,196.26. The trade was a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Zoetis Stock Down 0.0 %

NYSE:ZTS opened at $164.95 on Friday. The firm has a market capitalization of $73.86 billion, a price-to-earnings ratio of 30.16, a PEG ratio of 2.78 and a beta of 0.90. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $200.53. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. The business’s fifty day moving average price is $166.25 and its 200 day moving average price is $177.49.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, beating analysts’ consensus estimates of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The firm had revenue of $2.32 billion for the quarter, compared to the consensus estimate of $2.30 billion. On average, sell-side analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be paid a $0.50 dividend. The ex-dividend date is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a yield of 1.21%. Zoetis’s dividend payout ratio (DPR) is currently 36.56%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.